Cti Biopharma Corp (CTIC): James A Bianco , President and CEO of Cti Biopharma Corp sold 10,000 shares on Jun 24, 2016. The Insider selling transaction was reported by the company on Jun 24, 2016 to the Securities and Exchange Commission. The shares were sold at $0.37 per share for a total value of $3,654.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 27, 2016, James A Bianco (President and CEO) sold 10,000 shares at $0.45 per share price.On Mar 4, 2016, Matthew Plunkett (EVP, Chief Business Officer) sold 10,000 shares at $0.59 per share price.Also, On Feb 26, 2016, Jack W Singer (EVP, Chief Scientific Officer) sold 15,000 shares at $0.63 per share price.On Nov 20, 2015, Louis A Bianco (EVP, Finance & Administration) sold 15,000 shares at $1.13 per share price.
Shares of CTI BioPharma Corp (CTIC) ended Friday, Jun 24, 2016 session in red amid volatile trading. The shares closed down -0.0326 points or -8.10% at $0.37 with 2,04,97,720 shares getting traded. Post opening the session at $0.3625, the shares hit an intraday low of $0.36 and an intraday high of $0.3799 and the price vacillated in this range throughout the day. The company has a market cap of $105 M and the number of outstanding shares has been calculated to be 28,29,30,070 shares. The 52-week high of CTI BioPharma Corp is $2.2301 and the 52-week low is $0.2514.
CTI BioPharma Corp. (CTI) formerly Cell Therapeutics Inc. is a biopharmaceutical company focused on the acquisition development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers. The Company is focused on commercializing PIXUVRI (pixantrone) or PIXUVRI in the European Union for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL) and conducting a Phase III clinical trial program of pacritinib for the treatment of adult patients with myelofibrosis to support regulatory submission for approval in the United States and Europe. It is also engaged in evaluating pacritinib in earlier clinical trials as treatment for other blood-related cancers. Its development product candidates include tosedostat and Opaxio.